Fecal calprotectin as an intestinal inflammation marker is elevated in glaucoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bourne RRA, Steinmetz JD, Saylan M et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob. Health 9(2), e144–e160 (2021).
  MedlineGoogle Scholar
• 2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11), 2081–2090 (2014).
  MedlineGoogle Scholar
• 3. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in glaucoma: from the back to the front of the eye, and beyond. Prog. Retin. Eye Res. 83, 100916 (2021).
  MedlineGoogle Scholar
• 4. Chaiwiang N, Poyomtip T. Microbial dysbiosis and microbiota–gut–retina axis: the lesson from brain neurodegenerative diseases to primary open-angle glaucoma pathogenesis of autoimmunity. Acta Microbiol. Immunol. Hung. 66(4), 541–558 (2019). • Revealed disparities in the compositions of gut microbiomes among patients with primary open-angle glaucoma.
  Medline CASGoogle Scholar
• 5. Donabedian P, Dawson E, Li Q, Chen J. Gut microbes and eye disease. Ophthalmic Res. 65(3), 245–253 (2022).
  Medline CASGoogle Scholar
• 6. Gong H, Zeng R, Li Q et al. The profile of gut microbiota and central carbon-related metabolites in primary angle-closure glaucoma patients. Int. Ophthalmol. 42(6), 1927–1938 (2022). • Revealed that gut microbiota were altered in primary angle-closure glaucoma patients compared with healthy subjects. Correlation with clinical presentations and microbiota suggests potential mechanisms of Retinal Ganglion Cell impairment and novel intervention targets.
  MedlineGoogle Scholar
• 7. Gong H, Zhang S, Li Q et al. Gut microbiota compositional profile and serum metabolic phenotype in patients with primary open-angle glaucoma. Exp. Eye Res. 191, 107921 (2020).
  Medline CASGoogle Scholar
• 8. Zhang Y, Zhou X, Lu Y. Gut microbiota and derived metabolomic profiling in glaucoma with progressive neurodegeneration. Front. Cell. Infect. Microbiol. 12(Aug), 1–12 (2022).
  CASGoogle Scholar
• 9. Chen H, Cho KS, Vu THK et al. Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. Nat. Commun. 9(1), 3209 (2018). •• Intestinal flora is crucial for the pathogenesis of glaucoma, as glaucomatous neural damage was not observed in germ-free mouse models of glaucoma.
  MedlineGoogle Scholar
• 10. Houser MC, Tansey MG. The gut–brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis. 3, 3 (2017). •• Showed that dysbiosis of the gut microbiome is associated with chronic intestinal inflammation.
  MedlineGoogle Scholar
• 11. Devos D, Lebouvier T, Lardeux B et al. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 50(1), 42–48 (2013).
  Medline CASGoogle Scholar
• 12. Shen T, Yue Y, He T et al. The association between the gut microbiota and Parkinson’s disease, a meta-analysis. Front. Aging Neurosci. 13, 636545 (2021).
  Medline CASGoogle Scholar
• 13. Doifode T, Giridharan VV, Generoso JS et al. The impact of the microbiota-gut–brain axis on Alzheimer’s disease pathophysiology. Pharmacol. Res. 164, 105314 (2021).
  Medline CASGoogle Scholar
• 14. Vernia F, Di Ruscio M, Stefanelli G, Viscido A, Frieri G, Latella G. Is fecal calprotectin an accurate marker in the management of Crohn's disease? J. Gastroenterol. Hepatol. 35(3), 390–400 (2020).
  MedlineGoogle Scholar
• 15. Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit. Rev. Clin. Lab. Sci. 56(5), 307–320 (2019).
  Medline CASGoogle Scholar
• 16. Koulaouzidis A, Nemeth A, Johansson GW, Toth E. Dissecting lewis score under the light of fecal calprotectin; an analysis of correlation of score components with calprotectin levels in capsule endoscopy. Ann. Gastroenterol. 28(2), 259–264 (2015).
  MedlineGoogle Scholar
• 17. Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35(9), 642–647 (2003).
  Medline CASGoogle Scholar
• 18. Narayanan M, Vasudevan D. Faecal calprotectin in inflammatory bowel diseases. Acta Sci. Paediatr. 5(1), 21–24 (2022).
  Google Scholar
• 19. Schwiertz A, Spiegel J, Dillmann U et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat. Disord. 50, 104–107 (2018).
  MedlineGoogle Scholar
• 20. Leblhuber F, Geisler S, Steiner K, Fuchs D, Schütz B. Elevated fecal calprotectin in patients with Alzheimer’s dementia indicates leaky gut. J. Neural Transm. 122(9), 1319–1322 (2015).
  Medline CASGoogle Scholar
• 21. Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson’s disease. Front. Neurosci. 13(SEP), 1–6 (2019). • Evaluated fecal calprotectin as a biomarker of gut inflammation.
  MedlineGoogle Scholar
• 22. Hor JW, Lim S, Khor ES et al. Fecal calprotectin in Parkinson’s disease and multiple system atrophy. J. Mov. Disord. 15(2), 106–114 (2022).
  MedlineGoogle Scholar
• 23. Dumitrescu L, Marta D, Dănău A et al. Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson’s disease. Front. Neurosci. 15(June), 689723 (2021).
  MedlineGoogle Scholar
• 24. Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut 70(10), 1978–1988 (2021).
  Medline CASGoogle Scholar
• 25. Suryono, Kido JI, Hayashi N, Kataoka M, Nagata T. Calprotectin expression in human monocytes: induction by Porphyromonas gingivalis lipopolysaccharide, tumor necrosis factor-α, and interleukin-1β J. Periodontol. 76(3), 437–442 (2005).
  Medline CASGoogle Scholar
• 26. Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand. J. Gastroenterol. 50(1), 74–80 (2014).
  Google Scholar
• 27. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 34(1), 50–54 (1999). •• The concentration of calprotectin in feces demonstrates a strong correlation with the localization of 111In-labeled leukocytes, aiding in the prediction of abnormal small bowel radiology. Fecal calprotectin is considered a ‘gold standard’ for detecting intestinal inflammation.
  Medline CASGoogle Scholar
• 28. Montalto M, Curigliano V, Santoro L et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am. J. Gastroenterol. 102(1), 132–136 (2007).
  Medline CASGoogle Scholar
• 29. Banerjee A, Srinivas M, Eyre R et al. Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice. Frontline Gastroenterol. 6(1), 20–26 (2015). •• Showed that fecal calprotectin can differentiate between irritable bowel syndrome and organic disease, particularly inflammatory bowel disease.
  MedlineGoogle Scholar
• 30. Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68, S1–S106 (2019). •• Fecal calprotectin is a useful surrogate marker of inflammatory activity in inflammatory bowel disease. A threshold of 250 μg/g provides better specificity.
  MedlineGoogle Scholar
• 31. Chang MH, Chou JW, Chen SM et al. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Mol. Med. Rep. 10(1), 522–526 (2014).
  Medline CASGoogle Scholar
• 32. Lee JY, Cevallos SA, Byndloss MX et al. High-fat diet and antibiotics cooperatively impair mitochondrial bioenergetics to trigger dysbiosis that exacerbates pre-inflammatory bowel disease. Cell Host Microbe 28(2), 273.e6–284.e6 (2020).
  Google Scholar
• 33. Cueto AFV, Álvarez L, García M et al. Candidate glaucoma biomarkers: from proteins to metabolites, and the pitfalls to clinical applications. Biology 10(8), 1–48 (2021).
  Google Scholar
• 34. Mastropasqua R, Agnifili L, Mastropasqua L. Structural and Molecular Tear Film Changes in Glaucoma. Current Medicinal Chemistry 26(22), 4225–4240 (2018).
  Google Scholar